Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. CORRESP Other Correspondence Between Filers and SEC Staff
  2. 4 Open-market sale COO and Secretary sold 7,500 shares at an average $20.28 ($152,135)
  3. 4 Open-market sale Chief Medical Officer sold 17,500 shares at an average $20.29 ($355,011)
  4. 4 Open-market sale President and CEO sold 18,333 shares at $20.76 ($380,593)
  5. UPLOAD Other SEC-generated Letter
  6. 4 Open-market sale COO and Secretary sold 7,500 shares at $18.77 ($140,775)
  7. 4 Open-market sale Chief Medical Officer sold 17,500 shares at an average $18.78 ($328,653)
  8. 4 Open-market sale President and CEO sold 18,333 shares at $19.07 ($349,610)
  9. 4 Derivatives Options or other derivatives
  10. 8-K Event Shareholder vote results
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Open-market sale COO and Secretary sold 7,500 shares at an average $22.05 ($165,350)
  19. 4 Open-market sale Chief Medical Officer sold 17,500 shares at an average $22.85 ($399,901)
  20. 4/A Open-market sale Chief Medical Officer sold 36,912 shares at an average $25.44 ($938,976)

Page 32 of 40 · 789 filings